Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma

Background:Aberrant activities of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling pathways have been implicated in the development and spread of various cancer entities, among them colorectal carcinoma (CRC). Transcription factors STAT3 and STAT1, both downstream effectors of interleukin (IL)-6 and its receptor, are involved in growth and developmental control of CRC cells. Constituents of the signalling network around IL-6 and STAT activation are discussed as potential biomarkers and therapeutic targets in CRC.Methods:By immunohistochemical analysis of a tissue microarray covering >400 CRC biopsies, the expression and activity status of STAT1, STAT3 as well as of IL-6 and the IL-6 receptor α-chain was determined. The outcome was correlated with clinical information and patients’ survival data. Colorectal carcinoma biopsies were also analysed for specific DNA-binding activity of STATs.Results:Statistical analysis showed tendential associations between individual STATs, IL-6/IL-6 receptor-α and clinicopathological parameters. The study revealed a significant correlation of high STAT1 activity with longer patient overall survival. Surprisingly, strong STAT3 expression in surgical specimens was correlated with an increase in median overall survival by about 30 months. Statistical analysis revealed that high expression levels of STAT1 and STAT3 were associated. This finding was backed up by biochemical data that showed simultaneous STAT1 and STAT3 DNA-binding activity in randomly selected CRC biopsies.Conclusion:By multivariate data analysis, we could show that STAT3 expression and activity constitutes an independent favourable prognostic marker for CRC.

[1]  A. Chalaris,et al.  Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease , 2012, Digestive Diseases.

[2]  I. Petersen,et al.  DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer , 2011, British Journal of Cancer.

[3]  J. Bosset,et al.  Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial , 2010, Journal of Clinical Pathology.

[4]  M. Neurath,et al.  Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. , 2008, Current drug targets.

[5]  Jongdae Lee,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.

[6]  A. Shiau,et al.  Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis , 2003, British Journal of Cancer.

[7]  H. Komoda,et al.  Interleukin-6 Levels in Colorectal Cancer Tissues , 1998, World Journal of Surgery.

[8]  R. Jove,et al.  Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. , 2007, Urology.

[9]  Yuan‐Chiang Chung,et al.  Anti‐interleukin‐6 receptor antibody inhibits the progression in human colon carcinoma cells , 2011, European journal of clinical investigation.

[10]  R. Moriggl,et al.  Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. , 2007, Neoplasia.

[11]  L. Klampfer.  The role of signal transducers and activators of transcription in colon cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[12]  A. Mansoor,et al.  pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation , 2009, Leukemia & lymphoma.

[13]  Yuan‐Chiang Chung,et al.  Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. , 2006, Anticancer research.

[14]  Liang-pu Zheng,et al.  Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model. , 2012, International journal of oncology.

[15]  R. Moriggl,et al.  STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter , 2011, Biological chemistry.

[16]  Ying-Xuan Chen,et al.  Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. , 2008, Neoplasia.

[17]  D. Hori,et al.  Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma , 2009, British Journal of Cancer.

[18]  Yun Cui,et al.  Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal Transition* , 2011, The Journal of Biological Chemistry.

[19]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[20]  J. Bromberg,et al.  Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Ilyas,et al.  Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer , 2010, Gut.

[22]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[23]  Toshio Tanaka,et al.  Therapeutic targeting of the interleukin-6 receptor. , 2012, Annual review of pharmacology and toxicology.

[24]  Y. Toiyama,et al.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer , 2010, British Journal of Cancer.

[25]  Sung-Chul Lim,et al.  Significance of p-STAT3 expression in human colorectal adenocarcinoma. , 2008, Oncology reports.

[26]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[27]  C. Marth,et al.  Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Moriggl,et al.  Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metal loproteinase Induction , 2007 .

[29]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[30]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[31]  I. Petersen,et al.  Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma , 2011, Journal of Clinical Pathology.

[32]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[33]  Francesco Novelli,et al.  Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. , 2008, Seminars in cell & developmental biology.

[34]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[35]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[36]  Myung-Shik Lee,et al.  STAT1 as a key modulator of cell death. , 2007, Cellular signalling.

[37]  T. Nagayasu,et al.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors , 2005, Journal of Clinical Pathology.

[38]  T. Nakayama,et al.  Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. , 2007, International journal of oncology.

[39]  Toshiyuki Nakayama,et al.  Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. , 2006, Oncology reports.

[40]  I. Petersen,et al.  Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma , 2012, International Journal of Colorectal Disease.

[41]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.